Healthtech Startups
17,200 companies tagged Healthtech, with their investors and founders.
0 investors
Radwave develops an electromagnetic tracking platform for surgical navigation and interventional procedures that provides high accuracy and resistance to electromagnetic interference. The platform is designed for clinical use in minimally invasive and interventional medical applications.
0 investors
Rafael Holdings is a publicly traded (NYSE: RFL) company focused on the discovery and development of oncology therapeutics through a wholly-owned portfolio of companies, with multiple clinical programs including two Phase 3 trials. It is transitioning from a clinical-stage company toward a commercial pharmaceutical enterprise.
0 investors
0 investors
0 investors
0 investors
Raleigh Radiology is a radiology practice offering diagnostic and interventional imaging services—including MRI, CT, mammography, ultrasound, PET-CT, and nuclear medicine—across nine locations in the Triangle area of North Carolina. It serves patients and referring physicians with subspecialty expertise in musculoskeletal, abdominal, women's, pediatric, neuroradiology, and vascular imaging.
0 investors
0 investors
Rampart develops radiation shielding solutions for interventional medical procedures, offering lead-free protective equipment including ceiling-mounted shields, mobile barriers, and monitoring systems for interventional radiology and cardiology labs.
0 investors
0 investors
0 investors
0 investors
Ratio Therapeutics develops radiopharmaceuticals for oncology, working on targeted radiochemistry, discovery, and preclinical and clinical development. The company operates in the biotech and medtech space focused on molecular imaging and radiotherapy.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
ReadyWorks Health provides a workflow platform that digitizes paper-based checklists, forms, and daily logs using QR codes, giving hospitals analytics, notifications, and healthcare-specific workflows for equipment checks, compliance, and Joint Commission preparedness. It targets chief nursing officers at hospitals and clinics, with plans to extend to other highly-regulated industries.
0 investors
ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
0 investors
0 investors
0 investors
0 investors